Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
PSMA targeted PET/CT: Pearls and Pitfalls
June 20, 2024 | 3 p.m.
There are currently 3 PSMA-targeted PET radiotracers. We will compare the radioisotope used in these tracers, as well as the chemical structure of the agents and how this may affect imaging results. We will then review strengths and weaknesses of PSMA-targeted imaging to assist with optimal interpretation.
This webinar was developed and sponsored by Lantheus and is intended for healthcare professionals only.
Gary Ulaner, MD
Dr. Gary Ulaner is the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy (MIT) at the Hoag Family Cancer Institute and Professor of Radiology and Translational Genomics at the University of Southern California.
Gary has been the principal investigator of prospective clinical trials for eight novel PET radiotracers for patients with breast cancer, prostate cancer and myeloma, funded by two National Institutes of Health R01s, as well as grants from the Department of Defense (DoD) Breast Cancer Research Programs, Susan G. Komen Foundation, and Rising Tide Foundation. His clinical trials emphasize targeted imaging to guide targeted therapy of cancer, particularly ER, HER2, PSMA and CD38 targeted PET imaging.
Gary is on the editorial board of 4 leading radiology journals, authored the text “Fundamentals of Oncologic PET/CT”, and is on the scientific advisory boards of GE Healthcare, Lantheus, ImaginAb, Nuclidium, Precirix, and the Lobular Breast Cancer Alliance.